vandetanib
Selected indexed studies
- Vandetanib photoinduced cutaneous toxicities. (Cutis, 2019) [PMID:31233590]
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. (J Clin Oncol, 2012) [PMID:22025146]
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. (Endocr Relat Cancer, 2024) [PMID:38828895]
_Worker-drafted node — pending editorial review._
Connections
vandetanib is a side effect of
Sources
- Vandetanib photoinduced cutaneous toxicities. (2019) pubmed
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. (2012) pubmed
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. (2024) pubmed
- Vandetanib therapy in medullary thyroid cancer. (2012) pubmed
- Vandetanib for the treatment of thyroid cancer: an update. (2014) pubmed
- Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. (2006) pubmed
- Vandetanib for the treatment of medullary thyroid cancer. (2013) pubmed
- Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. (2013) pubmed
- The safety of vandetanib for the treatment of thyroid cancer. (2016) pubmed
- Vandetanib: An overview of its clinical development in NSCLC and other tumors. (2010) pubmed